Today (April 24), Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) treatment in the European Union (EU).

Related Keywords

Barcelona , Comunidad Autonoma De Cataluna , Spain , Antonio Alcaraz , Ahsan Arozullah , Naoki Okamura , European Medicines Agency , Committee For Medicinal Products Human Use , Drug Administration , University Hospital Clinic Of Barcelona , University Hospital Clinic , Europa Uomo , Medicinal Products , Human Use ,